# Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC

> **NCT03428022** · PHASE3 · UNKNOWN · sponsor: **Shenzhen People's Hospital** · enrollment: 54 (estimated)

## Conditions studied

- NSCLC
- Apatinib
- EGFR-TKI

## Interventions

- **DRUG:** Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）

## Key facts

- **NCT ID:** NCT03428022
- **Lead sponsor:** Shenzhen People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2019-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03428022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03428022, "Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03428022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*